Payment overview · 2025
General Payments
$136.10
9 reported records · 5 companies
Healthcare provider profile · identity verified
Jeremiah Nugent, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WYNNE, AR · NPI 1659735421
Verified facts
What the public records show
CMS Open Payments records show Jeremiah Nugent, M.D. received $136.10 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.57 | 32.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.79 | 22.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.41 | 21.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.20 | 12.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.13 | 10.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $136.10 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $44.57 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 315 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 213 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 211 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 26 |
| Lorazepam | Lorazepam | 166 | 30 |
| Lisinopril | Lisinopril | 155 | 43 |
| Alprazolam | Alprazolam | 149 | 20 |
| Gabapentin | Gabapentin | 147 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 126 | 19 |
| Furosemide | Furosemide | 120 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 18 |
| Prednisone | Prednisone | 113 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 22 |
| Pregabalin | Pregabalin | 102 | 16 |
| Tramadol Hcl | Tramadol Hcl | 102 | 25 |
| Metformin Hcl | Metformin Hcl | 101 | 24 |
| Meloxicam | Meloxicam | 100 | 20 |
| Omeprazole | Omeprazole | 98 | 15 |
| Glimepiride | Glimepiride | 91 | 18 |
| Losartan Potassium | Losartan Potassium | 91 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 29 |
| Eliquis | Apixaban | 86 | 15 |
| Potassium Chloride | Potassium Chloride | 78 | 18 |
| Clonazepam | Clonazepam | 77 | 12 |
| Sertraline Hcl | Sertraline Hcl | 77 | 14 |
| Azithromycin | Azithromycin | 69 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 12 |
| Aripiprazole | Aripiprazole | 68 | suppressed |
| Carvedilol | Carvedilol | 64 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | suppressed |
| Celecoxib | Celecoxib | 63 | 19 |
| Simvastatin | Simvastatin | 63 | 16 |
| Metformin Hcl Er | Metformin Hcl | 61 | 14 |
| Ozempic | Semaglutide | 61 | suppressed |
| Allopurinol | Allopurinol | 60 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 20 |
| Ondansetron Odt | Ondansetron | 52 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | suppressed |
| Novolog Flexpen | Insulin Aspart | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 44 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 11 |
| Cephalexin | Cephalexin | 43 | 33 |
| Glipizide | Glipizide | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 16 |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 25 |
| Levofloxacin | Levofloxacin | 27 | 23 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 14 |
| Naproxen | Naproxen | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.10 · 9 records | AstraZeneca Pharmaceuticals LP | BREZTRI, ELIQUIS, NURTEC ODT, Ozempic, PAXLOVID, REXULTI, Rybelsus, TRELEGY ELLIPTA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error